New asthma treatment begins human testing
NCT ID NCT06213844
Summary
This early-stage study tested the safety of a new asthma drug called IBI3002 in healthy volunteers and people with mild to moderate asthma. Researchers gave single doses to 52 participants to check for side effects and see how the drug moves through the body. The main goal was to determine if the drug is safe enough for further testing, not to treat asthma symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
Conditions
Explore the condition pages connected to this study.